Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Subscribe To Our Newsletter & Stay Updated